RWLK REWALK ROBOTICS LTD

Lifeward Cancels Its Extraordinary General Meeting of Shareholders

Lifeward Cancels Its Extraordinary General Meeting of Shareholders

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), today announced that it has cancelled its previously announced Extraordinary General Meeting of Shareholders that had been scheduled for January 13, 2025. The Board of Directors of Lifeward (the “Board”) has withdrawn from consideration by the shareholders of the Company the proposals set forth in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on November 25, 2024. The Company’s Board intends to present these proposals at a subsequent meeting in 2025.

About Lifeward

Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity System, the MyoCycle FES System, and the ReStore Exo-Suit.

Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit .

Lifeward®, ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "should," "would," "seek" and similar terms or phrases. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are more fully discussed in the Company’s periodic filings with the SEC, including the risk factors described under the heading "Risk Factors" in the Company’s annual report on Form 10-K and 10-K/A for the year ended December 31, 2023 filed with the SEC and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause the Company’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for the Company to predict all of them. Except as required by law, Lifeward undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Lifeward Media Relations:

Kathleen O’Donnell

VP Marketing & New Business Development

Lifeward Ltd.

E:

Lifeward Investor Contact:

Mike Lawless

Chief Financial Officer

Lifeward Ltd.

E: 



EN
13/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on REWALK ROBOTICS LTD

 PRESS RELEASE

Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilitie...

Lifeward to Acquire Powered Upper Body Exoskeleton with AI Capabilities Designed to Restore Function to Stroke Survivors IP and technology acquisition is expected to be highly accretive and to advance Lifeward’s position as a diversified biomedical innovation companyWill Expand Lifeward’s portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfolio Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- L...

 PRESS RELEASE

Lifeward Announces Reverse Share Split

Lifeward Announces Reverse Share Split Reverse split initiated as Lifeward enters strategic partnership agreement and repositions as MedTech innovation company HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced that effective with the open of the market on February 24, 2026, the Company will complete a 1-for-12 reverse split of its ordinary shares. On Janu...

 PRESS RELEASE

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage...

Lifeward’s ReWalk™ Personal Exoskeleton Now Covered by Aetna, Coverage Expands to Include Three of the Largest Medicare Advantage Insurers Aetna joins Humana and United Healthcare in providing Medicare Advantage coverage for beneficiaries who meet medical necessity criteria for the ReWalk Personal Exoskeleton Together, these three national Medicare Advantage insurers represent approximately 16 million beneficiaries across the United States HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global lead...

 PRESS RELEASE

Lifeward Enters Transformative Strategic Investment and Partnership Ag...

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to profitability and diversify its portfolio across MedTech and BioTech Lifeward acquires Oramed’s clinical-stage Protein Oral Delivery (POD™) technology adding exposure to a large, long-term Biotech market opportuni...

 PRESS RELEASE

Lifeward Appoints Bob Marshall as Chairman of the Board

Lifeward Appoints Bob Marshall as Chairman of the Board MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- ., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. “On behalf of the Board and e...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch